Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | CA5A | P35218 | 2/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL10425087 | 0.95 | TSHR (0.80) | TSHRMEN1ALDH1A1KMT2ACA5A | |
| Sulfuric Acid SCHEMBL30675348 | 0.95 | TSHR (0.80) | TSHRMEN1ALDH1A1KMT2ACA5A | |
| Sulfuric Acid SCHEMBL28085664 | 0.90 | TSHR (0.73) | TSHRMEN1ALDH1A1KMT2ACA5A | |
| Sulfuric Acid SCHEMBL17292833 | 0.90 | CA5A (0.60) | TSHRMEN1ALDH1A1KMT2ACA5A | |
| Sulfuric Acid SCHEMBL8524372 | 0.90 | TSHR (0.73) | TSHRMEN1ALDH1A1KMT2ACA5A | |
| Sulfuric Acid SCHEMBL28291978 | 0.90 | TSHR (0.73) | TSHRMEN1ALDH1A1KMT2ACA5A | |
| Sulfuric Acid SCHEMBL17183884 | 0.90 | TSHR (0.73) | TSHRMEN1ALDH1A1KMT2ACA5A | |
| Sulfuric Acid SCHEMBL9421407 | 0.90 | TSHR (0.73) | TSHRMEN1ALDH1A1KMT2ACA5A | |
| Sulfuric Acid SCHEMBL23211676 | 0.86 | TSHR (0.67) | TSHRMEN1ALDH1A1KMT2ACA5A | |
| Sulfuric Acid SCHEMBL17894339 | 0.86 | TSHR (0.67) | TSHRMEN1ALDH1A1KMT2ACA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5783822-A | Traceable well cement compositions and methods | HALLIBURTON ENERGY SERVICES, INC. (US) | 1998-07-21 | — | — | US | claimed |
| EP-0779409-A1 | Traceable well cement composition and its use | HALLIBURTON COMPANY (US) | 1997-06-18 | — | — | EP | claimed |
| US-20080213400-A1 | Combinations of Chromium with Antidiabetics for Glucose Metabolism Disorders | AKESIS PHARMACEUTICALS (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080181970-A1 | Combinations of Vanadium with Antidiabetics for Glucose Metabolism Disorders | AKESIS PHARMACEUTICALS (US) | 2008-07-31 | — | — | US | disclosed |
| WO-2008021210-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| US-20070293566-A1 | Combinations of vanadium with antidiabetics for glucose metabolism disorders | AKESIS PHARMACEUTICALS (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070281042-A1 | Combinations of chromium with antidiabetics for glucose metabolism disorders | AKESIS PHARMACEUTICALS (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070207218-A1 | Combinations of vanadium with antidiabetics for glucose metabolism disorders | AKESIS PHARMACEUTICALS (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070197425-A1 | Combinations of chromium with antidiabetics for glucose metabolism disorders | AKESIS PHARMACEUTICALS (US) | 2007-08-23 | — | — | US | disclosed |
| US-20070196512-A1 | Combinations of vanadium with antidiabetics for glucose metabolism disorders | AKESIS PHARMACEUTICALS (US) | 2007-08-23 | — | — | US | disclosed |
| WO-2000012080-A1 | DIET COMPOSITION AND METHOD OF WEIGHT MANAGEMENT | AMWAY CORPORATION (US) | 2000-03-09 | — | — | WO | disclosed |
| WO-1999037312-A1 | PHARMACEUTICAL COMPOSITION COMPRISING VANADIUM AND/OR SALTS THEREOF AND ITS USE TO TREAT BURNS | VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW (BE) | 1999-07-29 | — | — | WO | disclosed |
| US-5783822-A | Traceable well cement compositions and methods | HALLIBURTON ENERGY SERVICES, INC. (US) | 1998-07-21 | — | — | US | disclosed |
| EP-0779409-A1 | Traceable well cement composition and its use | HALLIBURTON COMPANY (US) | 1997-06-18 | — | — | EP | disclosed |
| US-5550113-A | MIXTURE OF INSULIN AND A METAL COMPLEX | MANN MORRIS A (US) | 1996-08-27 | — | — | US | disclosed |
| WO-1996002263-A1 | BLOOD SUGAR REGULATING COMPOSITIONS CONTAINING INULIN AND ONE OR MORE METAL COMPLEXES | MANN MORRIS A (US) | 1996-02-01 | — | — | WO | disclosed |
| EP-0304180-B1 | Stabilized antimicrobial agents, thermoplastic compositions containing same and products produced therefrom | BASF CORP (US) | 1993-10-20 | — | — | EP | disclosed |
| EP-0304180-A2 | Stabilized antimicrobial agents, thermoplastic compositions containing same and products produced therefrom | BASF Corporation (US) | 1989-02-22 | — | — | EP | disclosed |
| US-4769268-A | FREE RADICAL SCAVENGERS COMPRISING INORGANIC SALTS OR PIPERIDINE COMPOUNDS AS STABILIZERS | BASF CORPORATION (US) | 1988-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | TSHR 4669/4885MEN1 3687/4885ALDH1A1 2348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.